“…In terms of inclusion criteria regarding baseline comorbidity, 8 studies enrolled T2DM patients [ 21 , 23 , 25 , 26 , 27 , 28 , 30 , 32 ] (in 2 studies prediabetic patients were also included) [ 26 , 27 ], whereas the remaining 6 studies incorporated non-diabetic patients [ 22 , 24 , 29 , 31 , 33 , 34 ]. Seven trials were conducted in the United States [ 26 , 27 , 28 , 31 , 32 , 33 , 34 ]; 2 in Spain [ 21 , 25 ]; and 1 in Norway [ 22 ], Canada [ 23 ], Greece [ 24 ], China [ 29 ], and Australia [ 30 ] each. There was no significant between-group difference in serum levels of FG at pretreatment state in each study, with the mean value ranging from 84.3 to 185 mg/dL in ketogenic diet groups and from 80.2 to 170 mg/dL in comparator groups.…”